Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25225049 | 0.98 | SLC6A1 (0.41) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL5107282 | 0.85 | SLC6A1 (0.41) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL27589601 | 0.82 | GABRA5 (0.45) | SLC6A1SLC6A11SLC6A13TSHRLMNA | |
| SCHEMBL29017754 | 0.82 | MEN1 (0.36) | TSHRLMNAGABRR1 | |
| SCHEMBL20848235 | 0.82 | MEN1 (0.36) | TSHRLMNAGABRR1 | |
| SCHEMBL6679135 | 0.82 | MEN1 (0.36) | TSHRLMNAGABRR1 | |
| SCHEMBL1934562 | 0.82 | MEN1 (0.36) | TSHRLMNAGABRR1 | |
| SCHEMBL6679121 | 0.82 | MEN1 (0.36) | TSHRLMNAGABRR1 | |
| SCHEMBL12616436 | 0.82 | MEN1 (0.36) | TSHRLMNAGABRR1 | |
| SCHEMBL3257516 | 0.81 | ALOX5 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101555223-A | Pirlimycin intermediate and preparation method thereof | UNIV BEIJING CHEMICAL (CN) | 2009-10-14 | — | — | CN | claimed |
| WO-2018021977-A1 | GLYCINE METABOLISM MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | WO | disclosed |
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3174864-A2 | VMAT INHIBITORY COMPOUNDS | Oregon Health & Science University (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2016019312-A2 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-02-04 | — | — | WO | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
| CN-101555223-B | Pirlimycin intermediate and preparation method thereof | UNIV BEIJING CHEMICAL | 2011-06-01 | — | — | CN | disclosed |
| CN-101555223-A | Pirlimycin intermediate and preparation method thereof | UNIV BEIJING CHEMICAL (CN) | 2009-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | SLC6A1 8/4885SLC6A11 20/4885SLC6A13 22/4885 |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | SLC6A1 8/4885SLC6A11 20/4885SLC6A13 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.